Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1
In these pretreated participants, camizestrant 75 mg in combination with capivasertib 400 mg was well tolerated, with a side effect profile consistent with each drug as monotherapy, and showed encouraging evidence of clinical efficacy.
Authors
- Tony Jack
- Rhiannon Maudsley
- JPO Lindemann
- C. A. Morrow
- R.D. Baird
- Carmela Ciardullo (ORCID: https://orcid.org/0000-0002-0809-2136)
- Teresa Klinowska (ORCID: https://orcid.org/0000-0003-1997-7340)
- Christos Vaklavas (ORCID: https://orcid.org/0000-0002-9919-2748)
- Lisa Gibbons
- Tim Brier (ORCID: https://orcid.org/0009-0006-5218-1730)
- AC Armstrong
- C. Twelves
- I. Victoria Ruiz
- M. Oliveira
- B. Bermejo de las Heras
- A. Sykes
- I. Moreno
- A.M. Mathewson
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of Leeds (GB)
- University of Utah (US)
- Leeds Teaching Hospitals NHS Trust (GB)
- Huntsman Cancer Institute (US)
- Cancer Research UK (GB)
- University of Manchester (GB)
- Cancer Research UK Cambridge Center (GB)
- AstraZeneca (South Korea) (KR)
- Hospital Clínico Universitario de Valencia (ES)
- Hospital Clínic de Barcelona (ES)
- Vall d'Hebron Hospital Universitari (ES)
- The Christie NHS Foundation Trust (GB)
- Vall d'Hebron Institute of Oncology (ES)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1016/j.esmoop.2025.106049
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00